MedTrace Logo

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

NCT04955964 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2023-10-04

No results posted yet for this study

Summary

The main aim of this study is to learn about the safety profile of lanadelumab in teenagers and adults with hereditary angioedema (HAE) in Argentina as part of routine routine practice.

This study is about collecting data only. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. The study will collect data from the participant's medical records.

Participants do not need to visit their doctor in addition to their normal visits.

Conditions

  • Angioedemas, Hereditary

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2023-08-07
Completion
2023-08-07

Countries

  • Argentina

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04955964 on ClinicalTrials.gov